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Abstract
Background: Osteoporosis is one of the systemic features of COPD. A correlation between the emphysema phenotype
of COPD and reduced bone mineral density (BMD) is suggested by some studies, however, the mechanisms underlying
this relationship are unclear. Experimental studies indicate that IL-1b, IL-6 and TNF-a may play important roles in the
etiology of both osteoporosis and emphysema. The OPG/RANK/RANKL system is an important regulator of bone
metabolism, and participates in the development of post-menopausal osteoporosis. Whether the OPG/RANK/RANKL
pathway is involved in the pathogenesis of osteoporosis in COPD has not been studied.
Methods: Eighty male patients (current or former smokers) completed a chest CT scan, pulmonary function test,
dual x-ray absorptiometry measurements and questionnaires. Among these subjects, thirty patients with normal
BMD and thirty patients with low BMD were selected randomly for measurement of IL-1b, IL-6, TNF-a (flow
cytometry) and OPG/RANK/RANKL (ELISA). Twenty age-matched healthy volunteers were recruited as controls.
Results: Among these eighty patients, thirty-six had normal BMD and forty-four had low BMD. Age, BMI and CAT
score showed significant differences between these two COPD groups (p < 0.05). The low-attenuation area (LAA%)
in the lungs of COPD patients was negatively correlated with lumbar vertebral BMD (r = 0.741; p < 0.0001).
Forward logistic regression analysis showed that only LAA% (p = 0.005) and BMI (p = 0.009) were selected as
explanatory variables. The level of IL-1b was significantly higher in the COPD patients as compared to the normal
controls (p < 0.05), but the difference between the two COPD groups did not reach significance. The levels of IL-6
and TNF-a among the three groups were significantly different (p < 0.05). The level of RANKL and the RANKL/OPG
ratio were significantly higher in COPD patients with low BMD compared to those with normal BMD and the
normal controls (p < 0.05), and correlated negatively with lumbar vertebral BMD, but positively with LAA%.
Conclusions: Radiographic emphysema is correlated with low BMD in current and former smokers with COPD. IL-
1b, IL-6, TNF-a, and the osteoporosis-related protein system OPG/RANK/RANKL may have some synergetic effects
on emphysema and bone loss in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is
recognized as a highly prevalent condition which causes
significant morbidity and mortality [1], and commonly
associated with many extra-pulmonary abnormalities
such as cardiovascular disease, cachexia, skeletal muscle
wasting, and anemia [2,3]. Osteoporosis is one of the
most important systemic comorbidities in COPD, which
increases the risk of osteoporotic fractures, and carries a
heavy economic burden [4]. It has been reported that
bone mineral density (BMD) is lower in COPD patients
than in healthy subjects [5-7]. Studies have shown that
low BMD in COPD patients is related to some clinical
and physiological indices, such as lung function (FEV1),
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can be measured by Dual X-ray Absorptiometry (DXA).
With the advantages of high precision, short scan times,
and low radiation dose, DXA provides a noninvasive
method of diagnosing osteoporosis and guiding deci-
sions about treatment [10,11].
Emphysema is a primary imaging manifestation in
COPD patients, and has been recognized as an impor-
tant phenotype of COPD. The low-attenuation area
(LAA) in the lungs evaluated by chest CT images has
been widely used to quantitatively assess pulmonary
emphysema [12]. However, the association between
emphysema and osteoporosis in COPD patients and its
possible underlying mechanism are still unclear. In fact,
similarities between parenchymal emphysema and osteo-
porosis, including the loss of extracellular matrix and
common association with inflammatory mediators,
alludes to a potential mechanistic link between the two
processes.
Patients with COPD have evidence of systemic inflam-
mation, which may be responsible for some comorbid-
ities. Levels of inflammatory cytokines such as IL-1b, IL-
6 and TNF-a are increased in the systemic circulation of
COPD patients [13-15]. Inflammatory cytokines, includ-
ing IL-1b,I L - 6a n dT N F - a, are also responsible for the
characteristic loss of bone density in osteoporosis
through their effect on osteoclast activity [16,17]. The
osteoporosis related-protein triad osteoprotegerin
(OPG)/receptor activator of NF-B (RANK)/RANK
ligand (RANKL) has been identified as an important
regulator of bone metabolism and remodeling. This sys-
tem has been shown to interact with IL-1b,I L - 6a n d
TNF-a, and play important roles in the occurrence of
postmenopausal osteoporosis [18,19]. This raises the
intriguing possibility that the OPG/RANK/RANKL path-
way may also be involved in the development of osteo-
porosis in COPD.
Our hypothesis was that the extent of emphysema was
associated with the severity of osteoporosis in COPD
patients, and that pro-inflammatory cytokines and the
OPG/RANK/RANKL system were altered and correlated
with osteoporosis in these patients.
Methods
Subjects
Eighty male COPD patients diagnosed as clinically stable
were enrolled from January 2010 to May 2011. Female
patients were excluded from the study to avoid the
influence of postmenopausal osteoporosis. COPD was
diagnosed according to the criteria of the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) [2].
All patients were more than 40 years old, and were cur-
rent or former smokers. The exclusion criteria were as
follows: (1) acute exacerbation of COPD in the last 3
months, (2) history of respiratory diseases other than
COPD, (3) history of chest surgery, (4) occurrence of
malignancy within the previous five years, (5) history of
bone disease, (6) current and/or previous inhale, oral or
intravenous corticosteroid therapy, (7) other systemic
diseases, such as renal insufficiency and thyroid diseases,
or medication which may influence bone metabolism
within the previous one year.
The study was approved by the local ethics committee
of Beijing Tongren Hospital, Capital Medical University
(TRECKT 2008-14). All subjects provided informed con-
sent to join the study.
On the recruiting day, each subject completed a chest
CT scan, prebronchodilator and post-bronchodilator
spirometry and plethysmography, and DXA measure-
ments of BMD of the femoral neck and lumbar spine.
Recording of demographic parameters and medical his-
tory, evaluation of quality of life, and collection of blood
samples were also completed on that day.
Analysis of LAA
CT scans were performed using a multidetector row
scanner (Brilliance 64, Phillips, Eindhoven, Netherlands)
with technical parameters of 120 kVp, slice thicknesses
of 1.0 mm, and a thread interval of 11.08 mm. During
scanning, subjects were asked to hold their breath after
a deep inspiration in the supine position.
The percentage of LAA (LAA%) was measured auto-
matically using specified software in the Extended Brilli-
ance Workspace to quantitatively evaluate pulmonary
emphysema. All CT images from the upper margin of
the aortic arch to the diaphragm were used to calculate
the LAA%. Lung fields were defined as areas with a CT
scan density of less than -200 Hounsfield units (HU),
a n dt h et h r e s h o l db e t w e e nt h eL A Aa n dn o r m a ll u n g
density was defined as -950 HU. The LAA% was calcu-
lated as (number of LAA pixels in all slices)/(total lung
area)×100 (%). The measurements of LAA% were per-
formed independently by an experienced radiologist,
who was blinded to the subjects’ clinical information.
Measurements of BMD
BMD at the lumbar spine (L1-L4) and the bilateral
femoral neck was measured by Dual X-Ray Absorptio-
metry (Lunar prodigy, GE Healthcare, London, United
Kingdom). BMD is reported as an absolute value (g/
cm
2) and a T score, which represents the number of
standard deviations from a young, sex- and ethnic
group-specific reference mean. According to the defini-
tion of the World Health Organization (WHO), T scores
are used as the basis for diagnosis as follows: normal
bone mineral density: T score greater than -1 at both
sites (femoral neck and lumbar spine), osteopenia: T
score less than or equal to -1 but greater than -2.5 at
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-2.5 at either site [20]. On the basis of this standard, we
classified the subjects into two groups: COPD with nor-
mal BMD (T score greater than -1 at both sites) (36
patients) and COPD with low BMD (osteopenia/osteo-
porosis, T score less than or equal to -1 at either site)
(44 patients).
Measurements of IL-1b, IL-6, TNF-a and OPG/RANK/
RANKL
Among the eighty subjects, thirty patients with normal
BMD and thirty patients with low BMD were randomly
selected for the measurement of serum cytokines.
Twenty healthy volunteers (current or former smokers,
mean age: 58.4 ± 7.1), whose BMD at the lumbar spine
(L1-L4) and the bilateral femoral neck measured by
DXA were normal, were recruited as normal controls.
The smoking index showed no significant difference
among these three groups (p > 0.05). The exclusion cri-
teria were the same as those used for the COPD sub-
jects. Fasting blood samples (approximately 20 mL) were
collected by venipuncture in plain tubes. Sera were
obtained by centrifugation at 1000 × g for 5 min at
room temperature. The samples were stored at -80°C
until analysis. The levels of IL-1b,I L - 6 ,a n dT N F - a in
serum samples were evaluated by flow cytometry (CBA
Kit, BD Bioscience, USA). OPG/RANK/RANKL concen-
trations were measured by ELISA (Catalog No.CSB-
E04692h, 14931h, 08157h; Cusabio Biotech Co., Ltd,
USA). Assays were performed according to the manu-
facturer’s protocol.
Evaluation of Clinical Characteristics
Dyspnea was rated using the American Thoracic Society
MMRC dyspnea score [21].
Six-Minute Walking Distance (6MWD): The patients
walked in the same hospital hallway without oxygen
supplementation encouraged by a technician. Processing
was consistent with the ATS guidelines for the six min-
ute walk test [22].
BODE indices were calculated as the sum score pro-
posed by Celli et al. [23], based on the following four
variables: (1) FEV1 percentage of predicted (≥ 65%, score
0; 50% to 64%, score 1; 36% to 49%, score 2; and ≤ 35%,
score 3); (2) Six-minute walking distance (6MWD) (≥
350 m, score 0; 250 to 349 m, score 1; 150 to 249 m,
score 2; ≤149 m, score 3); (3) MMRC dyspnea score (0 to
1, score 0; 2, score 1; 3, score 2; and 4, score 3); and (4)
body mass index (BMI) (> 21 kg/m
2, score 0; ≤ 21 kg/m
2,
score 1). Possible total scores ranged from 0 to 10.
All patients were assessed by interview using the
COPD Assessment Test (CAT) [24], and the scores
were recorded.
Data analysis
All statistical analyses were performed using a statistical
software package (Statistics Package for the Social
Sciences, SPSS 17.0, Inc., Chicago, IL, USA). Data are
expressed as the mean ± SD. Comparisons of data
between two groups (COPD with normal BMD and
COPD with low BMD) were performed by T-test (for
normal distribution parameters) and Mann-Whitney U
test (for abnormal distribution parameters). Since the
subjects’ age among control, COPD with normal BMD
and COPD with low BMD groups had significant differ-
ence (p < 0.05), the comparisons of serum cytokines
were performed by analysis of covariance. The relation-
ships among continuous parameters were evaluated by
the multiple linear regression analyses. Based on the
grouping of BMD, forward logistic regression analyses
were performed to evaluate the contribution of LAA%
and other parameters which could cause a significant
difference between these two groups. A p value of <
0.05 was considered significant.
Results
Demographic parameters, pulmonary function results and
quality of life score of eighty COPD patients
Comparisons of age, BMI, FEV1/FVC, FEV1 % predicted,
CAT score and BODE index between the two COPD
groups (COPD with normal BMD and COPD with low
B M D )a r es h o w ni nT a b l e1 .A g e ,B M Ia n dC A Ts c o r e
showed significant differences between these two
groups, but there was no significant difference in FEV1/
FVC, FEV1 % predicted, smoking index and BODE
index.
CT scan measurements for pulmonary emphysema
As a quantitative assessment of pulmonary emphysema,
the mean value of LAA% for all 80 COPD patients was
24.66 ± 12.90%. Values of LAA% were 18.67 ± 10.00%
and 29.57 ± 13.03% for COPD with normal and low
BMD groups, respectively, with a significant difference
between groups (p < 0.0001).
BMD in the femoral neck and lumbar spine
To reduce the influence of BMD variability among ver-
tebral levels and between bilateral femoral necks, for
each patient, the mean BMD of four lumbar vertebrae
and of both femoral necks were used as the final results.
The mean BMD of the femoral neck showed a good
correlation with that of the lumbar vertebrae (r = 0.959;
p < 0.0001), a measurement which has been widely used
for the assessment of BMD (Figure 1). Therefore, we
used lumbar vertebral BMD to further analyze the cor-
relation of BMD with anthropometric parameters, qual-
ity of life score, and LAA%.
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RANK/RANKL
Serum levels of IL-1b,I L - 6 ,T N F - a and OPG/RANK/
RANKL were compared among the three groups (nor-
m a lc o n t r o l ,C O P Dw i t hn o r m a lB M Da n dC O P Dw i t h
low BMD) (Table 2). For adjustment of the effect of age,
analysis of covariance was used (age as the covariance).
The level of IL-1b was significantly higher in the
COPD patients as compared to the normal controls (p <
0.05), but the difference between the two COPD groups
did not reach significance. The levels of IL-6 and TNF-
a among the three groups were significantly different (p
<0 . 0 5 )( F i g u r e2 ) .N os i g n i f icant difference existed in
the level of OPG and RANK among the three groups,
but the level of RANKL (Figure 3) and the ratio of
RANKL/OPG (R/O) (Figure 4) were remarkably higher
in COPD patients with low BMD compared to those
with normal BMD and the normal controls (p < 0.05).
Correlation of BMD with pro-inflammatory cytokines and
OPG/RANK/RANKL concentration
Multiple linear regression analyses showed that, with the
adjustment of age, among IL-1b,I L - 6 ,T N F - a,O P G ,
RANK, RANKL and the ratio of RANKL/OPG, only the
level of RANKL (r = -0.256, p = 0.015) and the ratio of
RANKL/OPG (r = -0.258, p = 0.015) had a significant
negative correlation with lumbar vertebral BMD.
Correlation of pulmonary emphysema severity (LAA%)
with proinflammatory cytokines and OPG/RANK/RANKL
concentration
Multiple linear regression analyses showed that, with the
adjustment of age, among IL-1b,I L - 6 ,T N F - a,O P G ,
RANK, RANKL and the ratio of RANKL/OPG, only the
level of RANKL (r = 0.216, p = 0.043) and the ratio of
RANKL/OPG (r = 0.213, p = 0.041) had a significant
positive correlation with LAA%.
Correlation of BMD with pulmonary emphysema severity
(LAA%) and other variables
Pearson product-moment correlation analyses revealed
that LAA% had a significant negative correlation with
lumbar vertebral BMD (r = -0.741; p < 0.0001). Because
the complex relationship between COPD and osteoporo-
sis is confounded by the overlap of common risk factors,
a forward logistic regression analysis was performed,
based on the grouping of BMD and factors which
showed a significant difference between the two COPD
groups (i.e., LAA%, age, BMI and CAT) as independent
variables. This showed that only LAA% (p = 0.005) and
BMI (p = 0.009) were explanatory variables, indicating
that LAA% is the strongest predictor of osteopenia/
osteoporosis.
Discussion
COPD has been recognized as a systemic disease which
also involves several extra-pulmonary features. Osteo-
p o r o s i si so n eo ft h em a j o rs y stemic comorbidities of
COPD, which is more prevalent among COPD patients
Table 1 Comparison of demographic parameters, pulmonary function results and Quality of Life Score between two
COPD groups
Variables COPD with normal BMD (n = 36) COPD with low BMD (n = 44) p-value
Age(yr) 65.5 ± 5.1 67.8 ± 5.2 0.049
BMI(kg/m
2) 26.1 ± 3.6 23.5 ± 2.9 < 0.001
Smoking index(pack-yr) 28.1 ± 26.0 26.7 ± 21.6 0.79
CAT score 15.8 ± 9.6 21.0 ± 8.5 0.01
BODE index 3.3 ± 1.1 4.1 ± 1.2 0.26
FEV1/FVC(%) 57.0 ± 10.1 53.9 ± 9.6 0.17
FEV1 % predicted(%) 58.4 ± 19.2 52.8 ± 17.3 0.18
Data are mean (SD) unless otherwise stated.
COPD: chronic obstructive pulmonary disease, BMD: bone mineral density, BMI: body mass index, CAT: COPD Assessment Test, BODE index: body mass index,
airflow obstruction, dyspnea, and exercise capacity index, FEV1: forced expiratory volume in one second
Figure 1 Relationship between the average BMD of lumbar
spine bones and bilateral femoral necks. The average BMD of
femoral neck showed a good correlation with lumbar vertebra
(Average BMD of lumbar spine bones = 0.718 × Average BMD of
bilateral femoral necks +336.46;r = 0.959; p < 0.0001).
Bai et al. Respiratory Research 2011, 12:157
http://respiratory-research.com/content/12/1/157
Page 4 of 8than healthy subjects [5,8]. The etiology of COPD-
related osteoporosis is almost certainly multifactorial.
With the exception of BMI [6-9], the effects of other
factors which have been reported to be responsible for
the reduced bone density in patients with COPD, such
a sa g e[ 6 ] ,p o o rq u a l i t yo fl i f e[ 6 ] ,F E V 1 [6,9], smoking
[6], and corticosteroid therapy [6,8,25] remain contro-
versial. In our study, BMI was lower in the COPD with
low BMD group than the COPD with normal BMD
group, and logistic regression analysis showed that BMI
was an independent predictor for BMD. This result is in
accordance with previous studies [6-9]. In our study,
patients in both of the two COPD groups were older
than the control, and the COPD patients with low BMD
were older than those with normal BMD, the difference
among these three groups being significant (p < 0.05).
But age was not an independent variable in logistic
regression analysis. The effect of age on COPD-related
bone loss is still indefinite, and age may influence the
serum level of pro-inflammatory cytokines. Therefore,
when performing the data analysis, we used analysis of
covariance and multiple linear regression to correct the
influence of age. BMI and age are both correlated with
quality of life. CAT score and BODE index are two new
indices used to evaluate the quality of life for COPD
patients. The trend in our study showed that patients
with lower BMD had higher CAT scores (a relationship
which was statistically significant) and BODE index
(which did not reach statistical significance), indicating a
deterioration in the quality of life. This result agrees
with the findings of Iqbal et al. [6], showing that BMD
correlated weakly with activity evaluated by St George’s
respiratory questionnaire (SGRQ), whereas Katsura and
K i d a[ 7 ]a n dK j e n s l ie ta l .[ 8 ]d i dn o tf i n das i g n i f i c a n t
correlation with activity evaluated by the 6MWD. Sev-
eral studies have found no significant relationships
between bone density and airflow obstruction [7,26],
and these are in agreement with our study: FEV1/FVC
and FEV1 % predicted showed no significant difference
between the two COPD groups. In the study of Duckers
et al., over 80% of the male COPD with osteopenia/
Table 2 Comparison of IL-1b,IL-6, TNF-aand OPG/RANK/RANKL levels among three groups
Variables normal control (n = 20) COPD with normal BMD (n = 30) COPD with low BMD (n = 30)
IL-1b (fg/ml) 122.21 ± 35.14 186.83 ± 104.87† 192.94 ± 115.82†
IL-6(fg/ml) 354.37 ± 83.14 421.52 ± 125.78† 483.73 ± 110.38†‡
TNF-a (fg/ml) 193.09 ± 81.20 261.28 ± 96.09† 324.37 ± 141.29†‡
OPG(pg/ml) 236.50 ± 38.76 240.43 ± 65.77 257.97 ± 86.80
RANK(pg/ml) 82.28 ± 29.76 73.90 ± 50.41 2.24 ± 0.80 †‡
Data are mean (SD) unless otherwise stated.
†p < 0.05 compared with the normal control group.
‡p < 0.05 compared with the COPD with normal BMD group
COPD: chronic obstructive pulmonary disease, BMD: bone mineral density, IL: interleukin, TNF-a:tumor necrosis factor a, OPG: osteoprotegerin, RANK: receptor
activator of NF-B, RANKL: RANK ligand
Figure 2 Comparison of serum IL-1b, IL-6, TNF-a levels among
three groups. *p < 0.05. Abbreviations: IL: interleukin, TNF-a: tumor
necrosis factor a.
Figure 3 Comparison of serum OPG/RANK/RANKL levels
among three groups. *p < 0.05. Abbreviations: OPG:
osteoprotegerin, RANK: receptor activator of NF-B, RANKL: RANK
ligand.
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obstruction(GOLD I and II) [27]. Further studies are
needed to investigate the relationships between bone
density and airflow obstruction.
In the present study, we demonstrated that LAA%,
which reflects the extent of emphysema, correlated sig-
nificantly with reduced bone density. In addition, logistic
regression analysis showed that only LAA% and BMI
could predict bone density in male COPD patients. It
means that, in addition to the effect of BMI, LAA% is
also an independent predictor of bone loss and responsi-
b l ef o rt h ed i f f e r e n c ew h i c hw eh a sf o u n db e t w e e n
COPD patients with low BMD and those with normal
BMD. This result is in accordance with that of Ohara
and coworkers, who found a linear correlation between
emphysema and absolute BMD of the thoracic and L1
vertebrae measured by quantitative CT [28]. Recently, a
study by Bon and coworkers also showed that radio-
graphic emphysema was a strong, independent predictor
of low BMD in current and former smokers with COPD
[20]. These results provide support for the hypothesis
that emphysema itself could be a risk factor for bone
loss.
Destruction of the lung parenchyma may be associated
in some way with the mechanism of the destruction of
bone structure. The underlying mechanisms are specula-
tive and may be related to systemic inflammatory factors
acting synchronously on the lung parenchyma and bone
matrix. IL-1b,I L - 6a n dT N F - a are all well-established
inflammatory cytokines involved in the systemic inflam-
mation of COPD. In our study, the serum levels of IL-
1b,I L - 6a n dT N F - a in COPD patients were all signifi-
cantly higher than in controls, supporting the existence
of systemic inflammation in COPD. Bon and coworkers
have demonstrated an association between distinct
serum inflammatory mediators and quantitative CT
measurements of emphysema [29]. Simultaneously, IL-
1b,I L - 6a n dT N F - a have been shown to be important
modulators of bone metabolism and remodeling, by sti-
mulating osteoclast differentiation in a synergistic fash-
ion [16]. These cytokines may not only regulate
osteoclastogenesis via their effects on stromal cells, but
also act directly on osteoclasts and their precursors [30].
In addition, they also interact with the osteoporosis-
related OPG/RANK/RANKL protein system [18].
Recently, the OPG/RANK/RANKL system has been
shown to have pleiotropic effects on both bone metabo-
lism [31] and the immune system [32], and has led to a
new molecular perspective on osteoclast biology and
bone homeostasis. RANKL and OPG, synthesized by
stromal cells/osteoblasts, have been identified as two
principal cytokines controlling osteoclastic differentia-
tion and activation. RANK, localized at the cell surface
of mature osteoclasts and osteoclastic precursors, is the
third protagonist [33,34]. The predominant role of
RANKL in bone physiology is the stimulation of osteo-
clastic differentiation/activation and the inhibition of
osteoclast apoptosis [35]. Binding of RANKL to RANK
stimulates (1) differentiation of osteoclastic precursors
into mature osteoclasts, and (2) activation of mature
osteoclasts. OPG acts as a decoy receptor for RANKL
and thus down-regulates RANKL signaling through
RANK. It represents an endogenous decoy receptor that
neutralizes the biological effects of all forms of RANKL
and thus acts as an inhibitor of bone resorption [33,34].
In fact, bone remodeling appears to be mainly con-
trolled by the balance of RANKL/OPG. Any modifica-
tion in the RANKL-to-OPG ratio can induce either
excessive bone resorption or, in contrast, excessive bone
formation [35]. Dysregulation of their relative expression
can lead to pathological conditions such as osteopenia/
osteoporosis, bone tumor-associated osteolysis, immune
disease, or cardiovascular pathology [16]. It has been
demonstrated both in vivo and in vitro, that IL-1b,I L - 6
and TNF-a, which are the products of stromal cells and
monocytes, increase production of both RANKL and
OPG. The dominant outcome of these three cytokines is
a net increase in RANKL activity, which leads to bone
loss. In addition, increases of RANKL and OPG can also
up-regulate the expression of IL-6 and TNF-a [19],
which may enhance the systemic inflammation of
COPD.
In the present study, we found that the serum levels of
IL-6, TNF-a,R A N K La n dt h er a t i oo fR A N K L / O P G
were significantly higher in the COPD with low BMD
Figure 4 Comparison of RANKL/OPG among three groups.* p<
0.05. Abbreviations: OPG: osteoprotegerin, RANKL: receptor activator
of NF-B ligand.
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mal BMD); the level of IL-1b was also higher in the low
BMD group than in the normal BMD group, but did
not reach statistical significance. Only the level of
RANKL and the ratio of RANKL/OPG were significantly
correlated with lumbar vertebral BMD (negative) and
LAA% (positive).
It is well known that smoking can not only influence
the serum level of inflammatory cytokines (included IL-
1b,I L - 6 ,T N F - a and OPG/RANK/RANKL system), but
also accelerate the bone loss. In our study, patients and
the control were all current or former smokers, and the
smoking index showed no significant difference among
these three groups (p > 0.05). But further studies invol-
ving both smoking and non-smoking subjects are
needed.
In the study of Duckers et al., the serum level of OPG
was greater in COPD patients who combined with
osteopenia/osteoporosis than those without low BMD
and related inversely to hip BMD, but the level of
RANKL and the ratio of RANKL/OPG were not deter-
mined [27]. In our study, the level of OPG did not sig-
nificantly differ among these three groups. However, the
study of Eagan and coworkers found that the level of
OPG was significantly lower in COPD patients [36].
Both our study and that of Eagan et al. showed that, in
COPD patients, the balance of the OPG/RANK/RANKL
system is destroyed and manifests a dominant trend for
RANKL. Thus, we assume that systemic inflammation
may increase the serum levels of inflammatory cytokines
(especially, IL-6 and TNF-a), which then disturb the
balance of the OPG/RANK/RANKL system and result
in a dominant trend for RANKL. This trend may cause
the bone loss and osteopenia/osteoporosis seen among
COPD patients. Further studies will be necessary to vali-
date our hypothesis.
There are several limitations to our study. Firstly, the
subjects were all male. Female patients, who have been
reported to have a much higher incidence of osteope-
nia/osteoporosis, were not involved. Second, this study
did not include patients who never smoked. Third, the
size of the study population was relatively small. Further
studies, involving more patients, including both males
and females, as well as smoking and non-smoking sub-
jects, are necessary.
Conclusions
In conclusion, our study demonstrated that the extent
of pulmonary emphysema was significantly correlated
with reduced bone density, and for the first time to
our knowledge, that the level of RANKL and the
RANKL/OPG ratio were significantly higher in COPD
patients with low BMD compared to those with nor-
mal BMD, and correlated negatively with lumbar
vertebral BMD, but positively with LAA%. Although
o s t e o p o r o s i sr e s u l t sf r o mm u l t i p l ec a u s e ss u c ha sa g e ,
smoking, malnutrition, and steroid treatment, the sys-
temic inflammation of COPD may contribute directly
to osteoporosis to some extent. There may be conge-
nerous molecular mechanisms involved in the destruc-
tion of both lung parenchyma and bone structure, and
inflammatory cytokines, such as IL-1b,I L - 6a n dT N F -
a, as well as the osteoporosis related protein triad
OPG/RANK/RANKL, may have some synergetic effects
on both emphysema and bone loss. Further studies are
needed to explore the mechanisms underlying COPD-
related bone loss.
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